Total Holdings
33
Portfolio diversification across 33 positions
ARKG
(BATS)ARK Genomic Revolution ETF
$36.40-- (--)
Loading... - Market loading
ARKG ETF Holdings: ARK Genomic Revolution ETF
Complete portfolio holdings with allocation weights, sector breakdown, and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Assets Under Management
$1.26B
Total fund assets
Expense Ratio
0.75%
Annual management fee
Fund Issuer
ARK
BATS
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
Top 30 Holdings by Portfolio Weight
View ticker symbols, company names, asset types, and allocation percentages for each position
Scroll to see more
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 |  | Twist Bioscience Corporation | Stock | 10.80% |
| 2 |  | CRISPR Therapeutics AG | Stock | 8.28% |
| 3 |  | Tempus AI, Inc. Class A Common Stock | Stock | 8.02% |
| 4 |  | 10x Genomics, Inc. | Stock | 7.01% |
| 5 |  | Absci Corporation | Stock | 5.80% |
| 6 |  | Personalis, Inc. | Stock | 5.41% |
| 7 |  | Beam Therapeutics Inc | Stock | 4.83% |
| 8 |  | Guardant Health, Inc | Stock | 4.65% |
| 9 |  | Illumina, Inc | Stock | 4.52% |
| 10 |  | Natera, Inc | Stock | 4.25% |
| 11 |  | Veracyte, Inc | Stock | 3.44% |
| 12 |  | Intellia Therapeutics, Inc | Stock | 3.39% |
| 13 |  | CareDx, Inc | Stock | 3.21% |
| 14 |  | Recursion Pharmaceuticals, Inc. Class A Common Stock | Stock | 3.10% |
| 15 |  | COMPASS Pathways plc | Stock | 3.05% |
| 16 |  | Adaptive Biotechnologies Corporation | Stock | 2.44% |
| 17 |  | Nurix Therapeutics, Inc | Stock | 2.40% |
| 18 |  | Schrödinger, Inc | Stock | 2.20% |
| 19 |  | GeneDx Holdings Corp. | Stock | 1.93% |
| 20 |  | Butterfly Network, Inc. | Stock | 1.92% |
| 21 |  | Ionis Pharmaceuticals, Inc | Stock | 1.73% |
| 22 |  | Cerus Corporation | Stock | 1.61% |
| 23 |  | Arcturus Therapeutics Holdings Inc | Stock | 1.57% |
| 24 |  | AtaiBeckley Inc. | Stock | 1.26% |
| 25 |  | 908 Devices Inc. | Stock | 1.17% |
| 26 |  | Prime Medicine Inc. Common Stock | Stock | 1.15% |
| 27 |  | Pacific Biosciences of California, Inc | Stock | 1.08% |
| 28 |  | Eli Lilly and Company | Stock | 1.04% |
| 29 |  | BioNTech SE | Stock | 0.92% |
| 30 |  | Quantum-Si incorporated | Stock | 0.54% |
Frequently Asked Questions About ARK Genomic Revolution ETF Holdings
What are the top holdings in ARKG?
ARK Genomic Revolution ETF (ARKG) holds 33 securities. View the complete list of top holdings sorted by portfolio weight, showing each security's ticker symbol, company name, asset type, and allocation percentage.
How concentrated is ARKG's portfolio?
Portfolio concentration is measured by the weight of top holdings. A concentrated portfolio has fewer large positions with higher individual weights, while a diversified portfolio distributes holdings more evenly. Review ARKG's holdings table to analyze concentration risk.
What is ARKG's sector allocation?
The Sector Allocation chart shows how ARKG distributes investments across different industries like Technology, Healthcare, Financials, and more. This sector exposure helps understand the fund's industry diversification strategy.
What countries does ARKG invest in?
ARKG's geographic exposure is shown in the Countries tab under Portfolio Allocations. This reveals the fund's international diversification and exposure to different regions and global markets.
How diversified is ARKG ETF?
ARKG's diversification can be assessed by reviewing its 33 holdings, sector allocation, and geographic exposure. A well-diversified ETF spreads investments across multiple securities, sectors, and regions to reduce concentration risk.